October 20, 2021

Dupixent® (dupilumab) can now be used to treat asthma in a wider age group, as the U.S. FDA has expanded its asthma indication to include children ages 6-11 years. It was previously approved to treat asthma only in adults and in children at least 12 years old.

  • Under the indication, Dupixent is approved as an add-on maintenance therapy for moderate-to- severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent
  • Recommended dosing for children 6-11 years old is based on weight and whether the patient also has moderate-to-severe atopic
  • Dupixent first received FDA approval in 2017 and is also indicated to treat moderate-to-severe atopic dermatitis (ages 6 years and up) and chronic rhinosinusitis with nasal polyposis (adults).
November 19, 2021

COVID-19 Booster Shots Authorized for All Adults

Read More
November 18, 2021

New Warning Added to Climara Pro Prescribing Information

Read More
November 15, 2021

Besremi Approved for Rare Cancer

Read More
November 15, 2021

Mvasi Receives New Cancer Indication

Read More